3 Small Biotechs Turn on the Revenue Jets

The second-quarter earnings season is over for all intents and purposes. It was the second quarter in a row that the S&P 500 saw more than 20% year-over-year profit growth. In today's column we will look at some small biotech and biopharma names that are seeing huge revenue growth as they continue on their path to eventual profitability.

We will start with BioDelivery Sciences International Inc. (BDSI) , which reported second-quarter results after the bell on Thursday. The company delivered another quarter of 40% revenue growth and also addressed its capital needs during the quarter. Belbuca, accounting for about 80% of overall sales, saw sequential script growth of more than 30% from the first quarter and is on track to deliver more than $40 million in sales this year. BioDelivery Sciences believes this product can generate peak sales in the neighborhood of $200 million, which is less than the company's market capitalization....300 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.

Read the full story and get access to the Real Money Pro trading floor.

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a Subscriber? Please login.

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.